Rib-X Pharmaceuticals, an antibiotics company, has announced the appointment of Peter Greenleaf to the company's board of directors  succeeding Tony Zook.

Mr Greenleaf is the senior vice president of commercial operations, corporate development and strategy at MedImmune, and is also accountable for MedImmune Ventures, a corporate venture capital fund within the AstraZeneca/MedImmune group of companies.

Mr Greenleaf joined MedImmune from Centocor, where he served as franchise vice president, responsible for sales, marketing, strategic planning and business development. Previously, he served in sales and marketing capacities with Boehringer Mannheim Corporation and US Healthcare.

Susan Froshauer, founder and the president and CEO of Rib-X Pharmaceuticals, said: "Rib-X is very excited that Mr Greenleaf has joined our Board. His extensive commercial and strategic expertise and depth of hands-on experience in pharmaceutical sales and marketing is invaluable to Rib-X as we move our lead antibiotic programs into late-stage development.

Comments

Search RSS

All rights reserved."